摘要
目的:研究胰腺癌患者血清YKL-40和TPS表达及其临床意义。方法:采用YKL-40ELISA试剂盒、TP-STMELISA试剂盒和CA19-9ELISA试剂盒分别检测血清YKL-40、TPS和CA19-9。结果:胰腺癌患者的血清TPS全部在临界值(100U/L)以上,正常人中有2位分别为100和130U/L;52例胰腺癌患者中,血清CA19-936例在临界值(37U/mL)以上,在正常人中3位超过临界值。TPS的敏感性及特异性分别是100%和91%;CA19-9的分别为69%和86%。TPS和CA19-9合用后的敏感性及特异性为100%和82%。分层分析表明,血清TPS与胰腺癌分期无关。胰腺癌患者血清YKL-40显著高于正常组,Ⅰ、Ⅱ期与Ⅲ、Ⅳ期比较,差异有统计学意义,P<0·05。结论:TPS有助于胰腺癌的确诊和早期诊断,是一个独立的指标;在诊断胰腺癌的特异性和敏感性方面高于CA19-9;YKL-40是一个独立的指标,YKL-40和TPS联合检测有助于胰腺癌的早期诊断和临床分期。肿瘤防治杂志,2005,12(19)
OBJECTIVE： To investigate the clinical significance of serum YKL-40 and TPS in patients with pancreatic cancer. METHODS： YKL-40, TPS and CA19-9 levies were determined using the YKL-40 ELISA kit, TPSTMELISA kit and CA19-9 ELISA kit according to the manufacturer＇s protocol. RESULTS： Sreum CA19-9 （〉37U/L） has been found in 36 patients with pancreatic cancer and 3 normal persons. Sreum TPS （〉100 U/L） has been found in all patients with pancreatic cancer, independent of tumor clinical stages. The specificity and sensitivity of the TPS and CA19-9 were 100%, 91% and 69%,86% ,but they were 100%,82%. When the TPS and CA19-9 were united. High sreum YKL-40 has been found in patients with pancreatic cancer in different status, espetially in the stages Ⅲ and Ⅳ when pancreatic cancer invading periferal tissues, P〈0.05. CONCLUSIONS： YKL-40 is a independent marker. We can use YKL-40 and CT to determine weather the mass can be sectioned. That the surveillance of YKL-40 and CA19-9 together is helpful to the diagnosis of pancreatic cancer. TPS is helpful to the clear and early dianosis,and it is also a independent marker. TPS is superior to CA19-9 in the specificity and sensitivity of the diagnosis of pancreatic carcinoma. We can use TPS and CT to determine when diagnosing pancreatic carcinoma. That the surveillance of YKL-40 and TPS together is helpful to the early diagnosis and clinical tumor stages of-pancreatic cancer.
出处
《肿瘤防治杂志》
2005年第19期1483-1485,共3页
China Journal of Cancer Prevention and Treatment
作者简介
田禾,男,山东济南人,主治医师,主要从事肿瘤内科的研究工作.Tel：86-531-87984777-82769 通讯作者
